3 Lesser-Known Biotech Stocks That Are Surging

Last week, BGNE announced that its anti-PD-1 antibody, tislelizumab, has been approved by the China National Medical Products Administration (NMPA) to be combined with two chemotherapy regimens to cure non-small cell lung cancer.

The Street estimates BGNE’s revenue for the quarter ended December 31, 2020, to be $116.4 million, representing a 104.6% increase year-over-year. Meanwhile, its EPS is likely to rise at the rate of 24% per annum over the next five years.

BGNE has rallied 109.4% over the past year to close yesterday’s trading session at $356.68. The stock has climbed 43.4% over the past six months.

How does BGNE stack up for the POWR Ratings?

A for Trade Grade

A for Buy & Hold Grade

A for Peer Grade

B for Industry Rank

A for Overall POWR Rating

The stock is also ranked #10 of 239 stocks in the Medical – Pharmaceuticals Industry.

Alnylam Pharmaceuticals, Inc. (ALNY - Get Rating)

ALNY discovers, develops, and commercializes RNA interference (RNAi) therapeutics. Some of its investigational RNAi therapeutics deal with cardio-metabolic diseases, genetic medicines, hepatic infectious diseases, and diseases related to the central nervous system. ONPATTRO (patisiran), a lipid complex injection, and GIVLAARI, for curing acute hepatic porphyria (AHP) in adults, are among the company’s main products.

ALNY announced positive top-line results from phase III clinical trials for HELIOS, an investigational RNAi therapeutic that is being developed for treating transthyretin-mediated (ATTR) amyloidosis with polyneuropathy.

ALNY’s total revenue during the third quarter ended September 30, 2020, soared 79.6% year-over-year to $125.8 million. Meanwhile, the loss per share expanded to $2.18 compared to $1.92 posted in the same period last year. At the end of the quarter, ALNY had more than  1,150 patients worldwide using commercial ONPATTRO, while for GIVLAARI it had more than 150 patients globally.

View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.